The active metabolite of leflunomide, A77 1726, protects rat hepatocytes against bile acid-induced apoptosis

Journal of Hepatology

Volumn 49, Issue 5, 2008, Pages 799-809

  Vrenken, Titia E ^a   Buist Homan, Manon ^a   Kalsbeek, Allard Jan ^a   Faber, Klaas Nico ^a   Moshage, Han ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Apoptosis; Bile acids; Caspases; Leflunomide; Signal transduction

Indexed keywords

ACRIDINE ORANGE; BILE ACID; CASPASE; DACTINOMYCIN; GLYCOCHENODEOXYCHOLIC ACID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MENADIONE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B; TERIFLUNOMIDE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DNA SEQUENCE; DOSE RESPONSE; DRUG EFFECT; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; LIVER CELL; LIVER PROTECTION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; WESTERN BLOTTING;

ANILINE COMPOUNDS; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; APOPTOSIS; BILE ACIDS AND SALTS; GLYCOCHENODEOXYCHOLIC ACID; HEPATOCYTES; HYDROXYBUTYRATES; ISOXAZOLES; MALE; MAP KINASE SIGNALING SYSTEM; NECROSIS; NF-KAPPA B; OXIDATIVE STRESS; RATS; RATS, WISTAR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 53249154270     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2008.07.019     Document Type: Article

References (36)

1. Reed J.C. Mechanisms of apoptosis. Am J Pathol 157 (2000) 1415-1430
2. Varghese J., Khandre N.S., and Sarin A. Caspase-3 activation is an early event and initiates apoptotic damage in a human leukemia cell line. Apoptosis 8 (2003) 363-370
3. Adams J.M., and Cory S. Apoptosomes: engines for caspase activation. Curr Opin Cell Biol 14 (2002) 715-720
4. Higuchi H., and Gores G.J. Bile acid regulation of hepatic physiology: IV. Bile acids and death receptors. Am J Physiol Gastrointest Liver Physiol 284 (2003) G734-G738
5. Rust C., Karnitz L.M., Paya C.V., Moscat J., Simari R.D., and Gores G.J. The bile acid taurochenodeoxycholate activates a phosphatidylinositol 3-kinase-dependent survival signaling cascade. J Biol Chem 275 (2000) 20210-20216
6. Kim J.S., He L., and Lemasters J.J. Mitochondrial permeability transition: a common pathway to necrosis and apoptosis. Biochem Biophys Res Commun 304 (2003) 463-470
7. Cohen G.M. Caspases: the executioners of apoptosis. Biochem J 326 (1997) 1-16
8. Lemasters J.J. Mechanisms of hepatic toxicity - V. Necrapoptosis and the mitochondrial permeability transition: shared pathways to necrosis and apoptosis. Am J Physiol Gastrointest Liver Physiol 276 (1999) G1-G6
9. Latchoumycandane C., Seah Q.M., Tan R.C.H., Sattabongkot J., Beerheide W., and Boelsterli U.A. Leflunomide or A77 1726 protect from acetaminophen-induced cell injury through inhibition of JNK-mediated mitochondrial permeability transition in immortalized human hepatocytes. Toxicol Appl Pharmacol 217 (2006) 125-133
10. Imose M., Nagaki M., Kimura K., Takai S., Imao M., Naiki T., et al. Leflunomide protects from T-cell-mediated liver injury in mice through inhibition of nuclear factor kappaB. Hepatology 40 (2004) 1160-1169
11. Karaman A., Fadillioglu E., Turkmen E., Tas E., and Yilmaz Z. Protective effects of leflunomide against ischemia-reperfusion injury of the rat liver. Pediatr Surg Int 22 (2006) 428-434
12. Yao H.W., Li J., Chen J.Q., and Xu S.Y. Leflunomide attenuates hepatocyte injury by inhibiting Kupffer cells. World J Gastroenterol 10 (2004) 1608-1611
13. Alexander D., Friedrich B., Abruzzese T., Gondolph-Zink B., Wulker N., and Aicher W.K. The active form of leflunomide, HMR1726, facilitates TNF-alpha and IL-17 induced MMP-1 and MMP-3 expression. Cell Physiol Biochem 17 (2006) 69-78
14. Vergne-Salle P., Leger D.Y., Bertin P., Treves R., Beneytout J.L., and Liagre B. Effects of the active metabolite of leflunomide, A77 1726, on cytokine release and the MAPK signalling pathway in human rheumatoid arthritis synoviocytes. Cytokine 31 (2005) 335-348
15. Manna S.K., Mukhopadhyay A., and Aggarwal B.B. Leflunomide suppresses TNF-induced cellular responses: Effects on NF-kappa B, activator protein-1, c-Jun N-terminal protein kinase, and apoptosis. J Immunol 165 (2000) 5962-5969
16. Manna S.K., and Aggarwal B.B. Immunosuppressive leflunomide metabolite (A77 1726) blocks TNF-dependent nuclear factor-kappa B activation and gene expression. J Immunol 162 (1999) 2095-2102
17. Layseca-Espinosa E., Pedraza-Alva G., Montiel J.L., del Rio R., Fierro N.A., Gonzalez-Amaro R., et al. T cell aggregation induced through CD43: intracellular signals and inhibition by the immunomodulatory drug leflunomide. J Leukoc Biol 74 (2003) 1083-1093
18. Xu X., Williams J.W., Bremer E.G., Finnegan A., and Chong A.S. Inhibition of protein tyrosine phosphorylation in T cells by a novel immunosuppressive agent, leflunomide. J Biol Chem 270 (1995) 12398-12403
19. Latchoumycandane C., Goh C.W., Ong M.M., and Boelsterli U.A. Mitochondrial protection by the JNK inhibitor leflunomide rescues mice from acetaminophen-induced liver injury. Hepatology 45 (2007) 412-421
20. Migita K., Miyashita T., Maeda Y., Nakamura M., Yatsuhashi H., Ishibashi H., et al. An active metabolite of leflunomide, A77 1726, inhibits the production of serum amyloid A protein in human hepatocytes. Rheumatology 44 (2005) 443-448
21. Leger D.Y., Liagre B., and Beneytout J.L. Low dose leflunomide activates PI3K/Akt signalling in erythroleukemia cells and reduces apoptosis induced by anticancer agents. Apoptosis 11 (2006) 1747-1760
22. Karaman A., Iraz M., Kirimlioglu H., Karadag N., Tas E., and Fadillioglu E. Hepatic damage in biliary-obstructed rats is ameliorated by leflunomide treatment. Pediatr Surg Int 22 (2006) 701-708
23. Colic M., Popovic P., Vucevic D., and Dimitrijevic M. Leflunomide induces apoptosis of thymocytes and T-cell hybridoma: differences in sensitivity and signaling pathways. Transplant Proc 33 (2001) 2344-2346
24. Ghosh S., Zheng Y., Jun X., Narla R.K., Mahajan S., Navara C., et al. Alpha-cyano-beta-hydroxy-beta-methyl-N-[4-(trifluoromethoxy)phenyl] propenamide: an inhibitor of the epidermal growth factor receptor tyrosine kinase with potent cytotoxic activity against breast cancer cells. Clin Cancer Res 4 (1998) 2657-2668
25. Conde de la Rosa L., Schoemaker M.H., Vrenken T.E., Buist-Homan M., Havinga R., Jansen P.L., et al. Superoxide anions and hydrogen peroxide induce hepatocyte death by different mechanisms: involvement of JNK and ERK MAP kinases. J Hepatol 44 (2006) 918-929
26. Schoemaker M.H., Conde de La Rosa L., Buist-Homan M., Vrenken T.E., Havinga R., Poelstra K., et al. Tauroursodeoxycholic acid protects rat hepatocytes from bile acid-induced apoptosis via activation of survival pathways. Hepatology 39 (2004) 1563-1573
27. Blokzijl H., Vander B.S., Bok L.I., Libbrecht L., Geuken M., van den Heuvel F.A., et al. Decreased P-glycoprotein (P-gp/MDR1) expression in inflamed human intestinal epithelium is independent of PXR protein levels. Inflamm Bowel Dis 13 (2007) 710-720
28. Li E.K., Tam L.S., and Tomlinson B. Leflunomide in the treatment of rheumatoid arthritis. Clin Ther 26 (2004) 447-459
29. Holtmann M.H., Gerts A.L., Weinman A., Galle P.R., and Neurath M.F. Treatment of Crohn's disease with leflunomide as second-line immunosuppression: a phase 1 open-label trial on efficacy, tolerability and safety. Dig Dis Sci 53 (2008) 1025-1032
30. Kalgutkar A.S., Nguyen H.T., Vaz A.D., Doan A., Dalvie D.K., McLeod D.G., et al. In vitro metabolism studies on the isoxazole ring scission in the anti-inflammatory agent lefluonomide to its active alpha-cyanoenol metabolite A771726: mechanistic similarities with the cytochrome P450-catalyzed dehydration of aldoximes. Drug Metab Dispos 31 (2003) 1240-1250
31. Schoemaker M.H., Gommans W.M., Conde de la Rosa L., Homan M., Klok P., Trautwein C., et al. Resistance of rat hepatocytes against bile acid-induced apoptosis in cholestatic liver injury is due to nuclear factor-kappa B activation. J Hepatol 39 (2003) 153-161
32. Reinehr R., Graf D., and Haussinger D. Bile salt-induced hepatocyte apoptosis involves epidermal growth factor receptor-dependent CD95 tyrosine phosphorylation. Gastroenterology 125 (2003) 839-853
33. Reinehr R., and Haussinger D. Inhibition of bile salt-induced apoptosis by cyclic AMP involves serine/threonine phosphorylation of CD95. Gastroenterology 126 (2004) 249-262
34. Reinehr R., Becker S., Hongen A., and Haussinger D. The Src family kinase Yes triggers hyperosmotic activation of the epidermal growth factor receptor and CD95. J Biol Chem 279 (2004) 23977-23987
35. Reinehr R., Becker S., Wettstein M., and Haussinger D. Involvement of the Src family kinase yes in bile salt-induced apoptosis. Gastroenterology 127 (2004) 1540-1557
36. Osiri M., Shea B., Robinson V., Suarez-Almazor M., Strand V., Tugwell P., et al. Leflunomide for the treatment of rheumatoid arthritis: a systematic review and metaanalysis. J Rheumatol 30 (2003) 1182-1190